Galectin Therapeutics Secures $10 Million Credit Line, Advances Belapectin Program With FDA Feedback.
ByAinvest
Monday, Dec 22, 2025 2:57 am ET1min read
GALT--
Galectin Therapeutics has received written feedback from the FDA on its Belapectin program for MASH cirrhosis and portal hypertension. The FDA has aligned with Galectin on the patient population for a registration trial and plans to extend a follow-up Type C meeting to finalize trial design elements and present new biomarker data. Galectin has also secured a $10 million credit line to fund expenditures through at least March 2027.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet